LGND FY 2024 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$167M+27.3% YoY

Gross Profit

$156M93.4% margin

Operating Income

-$23M-13.5% margin

Net Income

-$4M-2.4% margin

EPS (Diluted)

$-0.22

Cash Flow

Operating Cash Flow

$97M

Free Cash Flow

$77M

Stock-Based Comp.

$41M

Balance Sheet

Total Assets

$942M

Total Liabilities

$111M

Stockholders' Equity

$830M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$167M	$131M	+27.3%
Gross Profit	$156M	$96M	+62.1%
Operating Income	-$23M	$12M	-289.3%
Net Income	-$4M	$52M	-107.7%